Hummingbird Bioscience is developing antibodies against a number of important oncology and immuno-oncology targets where we believe there is an opportunity create significant impact. All programs are either first in class or have a highly differentiated mechanism that offers the potential for best in class efficacy.
Boyd-Kirkup, J.D., Thakkar, D., Sancenon, V., Guan, S., Paszkiewicz, K., & Ingram, P.J. Abstract: 477: HMBD-002-V4 A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment. J. Immunother. Cancer, vol 6, no. S1, p. 115, Nov. 2018. https://doi.org/10.1186/s40425-018-0423-x
Boyd-Kirkup, J. D., Thakkar, D., Paszkiewicz, K., & Ingram, P. J. (2018). Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody. Cancer Research, 78(13 Supplement), 1729–1729. https://doi.org/10.1158/1538-7445.am2018-1729
Ingram, P. J., Thakkar, D., & Boyd-Kirkup, J. D. (2017). Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models. Cancer Research, 77(13 Supplement), 587–587. https://doi.org/10.1158/1538-7445.AM2017-587
Boyd-Kirkup, J. D., Thakkar, D., & Ingram, P. J. (2017). Abstract 24: HMBD001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors. Cancer Research, 77(13 Supplement), 24–24. https://doi.org/10.1158/1538-7445.AM2017-24
Boyd-Kirkup, J., Thakkar, D., Brauer, P., Zhou, J., Chng, W.-J., & Ingram, P. J. (2017). HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML. Blood, 130(Suppl 1). Retrieved from http://www.bloodjournal.org/content/130/Suppl_1/1378